Terms: = Breast cancer AND BCL7A, BCL7, 605, ENSG00000110987 AND Prognosis
20 results:
1. Preoperative Radiotherapy Does Not Change the Existing Treatment Paradigm in Stage III breast cancer.
He Y; Chen Q; Zhu F; Liu C; Shao Y; Liu H
Oncology; 2024; 102(4):310-317. PubMed ID: 37748458
[TBL] [Abstract] [Full Text] [Related]
2. Significance of Tumor-Stroma Ratio (TSR) in Predicting Outcomes of Malignant Tumors.
Pyo JS; Kim NY; Min KW; Kang DW
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512068
[No Abstract] [Full Text] [Related]
3. Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1).
Roser E; Harter P; Zocholl D; Denschlag D; Chekerov R; Wimberger P; Kurzeder C; Hasenburg A; Muallem MZ; Mustea A; Emons G; Zeimet AG; Beck F; Arndt T; Brucker SY; Kommoss S; Heitz F; Welz J; Egger EK; Kalder M; Buderath P; Klar M; Marth C; Ulrich UA; Weigel M; Traub L; Anthuber C; Strauss H; Hanker L; Link T; Kubiak K; Melekian B; Hornung D; Pölcher M; Lampe B; Krauß T; Keilholz U; Flörcken A; Pietzner K; Sehouli J
Int J Gynecol Cancer; 2023 Feb; 33(2):223-230. PubMed ID: 36631151
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events.
Zeng KL; Sahgal A; Tseng CL; Myrehaug S; Soliman H; Detsky J; Atenafu EG; Lee Y; Campbell M; Maralani P; Husain ZA
Neurosurgery; 2021 Apr; 88(5):971-979. PubMed ID: 33475723
[TBL] [Abstract] [Full Text] [Related]
5. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
Polley MC; Leon-Ferre RA; Leung S; Cheng A; Gao D; Sinnwell J; Liu H; Hillman DW; Eyman-Casey A; Gilbert JA; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari K; Couch F; Carter JM; Visscher DW; Nielsen TO; Goetz MP
Breast Cancer Res Treat; 2021 Feb; 185(3):557-566. PubMed ID: 33389409
[TBL] [Abstract] [Full Text] [Related]
6. bcl7C suppresses ovarian cancer growth by inactivating mutant p53.
Huang C; Hao Q; Shi G; Zhou X; Zhang Y
J Mol Cell Biol; 2021 May; 13(2):141-150. PubMed ID: 33306126
[TBL] [Abstract] [Full Text] [Related]
7. Incidence, prevalence, and outcomes of systemic malignancy with bone metastases.
Jiang W; Rixiati Y; Zhao B; Li Y; Tang C; Liu J
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020915989. PubMed ID: 32634071
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Features and Survival of Single Hormone Receptor-Positive breast cancer: A Population-Based Study of 531,605 Patients.
Lv M; Mao Y; Song Y; Wang Y; Liu X; Wang X; Nie G; Wang H
Clin Breast Cancer; 2020 Oct; 20(5):e589-e599. PubMed ID: 32565109
[TBL] [Abstract] [Full Text] [Related]
9. Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case-control study.
Deng Y; Zhou L; Li N; Wang M; Yao L; Dong S; Zhang M; Yang P; Hao Q; Wu Y; Lyu L; Jin T; Dai Z; Kang H
Mol Carcinog; 2019 Dec; 58(12):2218-2229. PubMed ID: 31489712
[TBL] [Abstract] [Full Text] [Related]
10. Low bcl7a expression predicts poor prognosis in ovarian cancer.
Sun Z; Sun L; He M; Pang Y; Yang Z; Wang J
J Ovarian Res; 2019 May; 12(1):41. PubMed ID: 31077237
[TBL] [Abstract] [Full Text] [Related]
11. The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer.
Lawrenson R; Lao C; Campbell I; Harvey V; Seneviratne S; Elwood M; Sarfati D; Kuper-Hommel M
N Z Med J; 2018 May; 131(1475):51-60. PubMed ID: 29771902
[TBL] [Abstract] [Full Text] [Related]
12. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract] [Full Text] [Related]
13. Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.
Schraa SJ; Frerichs KA; Agterof MJ; Hunting JCB; Los M; de Jong PC
Eur J Cancer; 2017 Jul; 79():152-157. PubMed ID: 28494406
[TBL] [Abstract] [Full Text] [Related]
14. Risk of premature menopause after treatment for Hodgkin's lymphoma.
Swerdlow AJ; Cooke R; Bates A; Cunningham D; Falk SJ; Gilson D; Hancock BW; Harris SJ; Horwich A; Hoskin PJ; Linch DC; Lister A; Lucraft HH; Radford J; Stevens AM; Syndikus I; Williams MV;
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25139687
[TBL] [Abstract] [Full Text] [Related]
15. Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis.
Serce NB; Boesl A; Klaman I; von Serényi S; Noetzel E; Press MF; Dimmler A; Hartmann A; Sehouli J; Knuechel R; Beckmann MW; Fasching PA; Dahl E
BMC Cancer; 2012 Dec; 12():597. PubMed ID: 23236990
[TBL] [Abstract] [Full Text] [Related]
16. Array-based DNA methylation profiling for breast cancer subtype discrimination.
Van der Auwera I; Yu W; Suo L; Van Neste L; van Dam P; Van Marck EA; Pauwels P; Vermeulen PB; Dirix LY; Van Laere SJ
PLoS One; 2010 Sep; 5(9):e12616. PubMed ID: 20830311
[TBL] [Abstract] [Full Text] [Related]
17. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract] [Full Text] [Related]
18. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract] [Full Text] [Related]
19. Histologic multifocality is predictive of skin recurrences after conserving treatment of stage I and II breast cancers.
Marret H; Perrotin F; Bougnoux P; Giraudeau B; Hubert B; Fetissof F; Le Floch O; Lansac J; Body G
Breast Cancer Res Treat; 2001 Jul; 68(1):1-8. PubMed ID: 11678304
[TBL] [Abstract] [Full Text] [Related]
20. Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer.
Marret H; Perrotin F; Bougnoux P; Descamps P; Hubert B; Lefranc T; Le Floch O; Lansac J; Body G
Breast Cancer Res Treat; 2001 Mar; 66(1):17-23. PubMed ID: 11368406
[TBL] [Abstract] [Full Text] [Related]
